Compared to A1, groups B1 and B2 included a greater proportion of patients with both MS and another AID (A1, seven cases [13.7%]; B1, nine [42.9%]; B2, four [40%]; p = .01) (Table 1). This evidence concerns the gene AICDA and myeloid sarcoma.